Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

27%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(33.3%)
Phase 2
3(33.3%)
Phase 3
3(33.3%)
9Total
Phase 1(3)
Phase 2(3)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT04635891Recruiting

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Role: collaborator

NCT07250737Unknown

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

Role: lead

NCT05747924Phase 1Completed

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Role: lead

NCT07008469Phase 3Enrolling By Invitation

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

Role: lead

NCT05027269Phase 1Completed

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Role: lead

NCT06411288Phase 3Active Not Recruiting

Global Study of Del-desiran for the Treatment of DM1

Role: lead

NCT07038200Phase 3Recruiting

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Role: lead

NCT05479981Phase 2Completed

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Role: lead

NCT05670730Phase 1Completed

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

Role: lead

NCT06244082Phase 2Active Not Recruiting

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

Role: lead

NCT06547216Phase 2Enrolling By Invitation

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Role: lead

All 11 trials loaded